Skip to main content

Bio-Techne Corp Value Stock - Dividend - Research Selection

Bio-techne

ISIN: US09073M1045 , WKN: A12ENG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Healthcare Stock Worth Your Attention and 2 We Question

2026-08-04
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

Madison Mid Cap Fund Q2 2026 Portfolio Activity

2026-07-31
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters.

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

2026-07-31
We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.

Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?

2026-07-29
TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.

What to Expect From Bio-Techne's Next Quarterly Earnings Report

2026-07-20
Bio-Techne is scheduled to post its fourth-quarter results soon, and analysts project a single-digit earnings decline.

Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks

2026-07-16
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.

Revvity: Overvalued On Sentiment

2026-07-13
Revvity, Inc. trades near 52-week highs, buoyed by sector M&A momentum but faces fundamental headwinds. Learn more about RVTY stock now.

Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover

2026-07-10
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.

Broadening Market Lifts Moat Stocks In June

2026-07-10
The S&P 500 declined 0.95% as market leadership rotated away from mega-cap tech. Read more here.

RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

2026-07-09
RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.